We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+18.1%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$422M
AUM Growth
+$62.2M
Cap. Flow
+$55.4M
Cap. Flow %
13.12%
Top 10 Hldgs %
68.75%
Holding
41
New
4
Increased
4
Reduced
14
Closed
3

Top Buys

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$20.3M
2
RGNX icon
Regenxbio
RGNX
+$18.4M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$13.8M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.77M
5
NTLA icon
Intellia Therapeutics
NTLA
+$4.65M

Top Sells

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$5.04M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$4.6M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$2.53M
4
FOLD
Amicus Therapeutics
FOLD
+$1.14M
5
NEO icon
NeoGenomics
NEO
+$1.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
26
Edgewise Therapeutics
EWTX
$4.64B
$2.99M 0.71%
+304,027
New +$3.07M
MDGL icon
27
Madrigal Pharmaceuticals
MDGL
$12.3B
$2.91M 0.69%
44,747
-253
-0.6% -$17.6K
RVMD icon
28
Revolution Medicines
RVMD
$44.6B
$2.88M 0.68%
146,041
– –
VSTM icon
29
Verastem
VSTM
$654M
$2.76M 0.65%
270,388
– –
PHAT icon
30
Phathom Pharmaceuticals
PHAT
$743M
$2.14M 0.51%
193,326
– –
AVDL
31
DELISTED
Avadel Pharmaceuticals
AVDL
$2.07M 0.49%
412,363
– –
MIRM icon
32
Mirum Pharmaceuticals
MIRM
$5.94B
$2.04M 0.48%
97,322
-191,209
-66% -$4.6M
ONCR
33
DELISTED
Oncorus, Inc.
ONCR
$2.02M 0.48%
2,377,031
– –
INZY
34
DELISTED
Inozyme Pharma
INZY
$1.77M 0.42%
661,144
-3,836
-0.6% -$13.9K
ADCT icon
35
ADC Therapeutics
ADCT
$146M
$1.61M 0.38%
334,384
– –
EPIX
36
DELISTED
ESSA Pharma
EPIX
$738K 0.17%
405,700
-255,192
-39% -$672K
TECX
37
Tectonic Therapeutic
TECX
$696M
$416K 0.1%
53,993
– –
BDTX icon
38
Black Diamond Therapeutics
BDTX
$128M
$405K 0.1%
239,888
– –
NEO icon
39
NeoGenomics
NEO
$2.32B
– –
-135,573
Closed -$1.1M
KRTX
40
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-20,000
Closed -$2.53M
EPZM
41
DELISTED
Epizyme, Inc
EPZM
– –
-3,425,202
Closed -$5.04M
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q3 2022 Portfolio in Review

As of Q3 2022, MPM BioImpact held 41 positions worth $422M, up 17% from $360M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

MPM BioImpact deployed $55.4M of net new capital in Q3 2022, opening 4 new positions and adding to 4 existing holdings. Its largest new stake was Verve Therapeutics: 635,792 shares worth $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Mirum Pharmaceuticals, an estimated $4.6M trimmed.

  • MPM BioImpact's largest Q3 2022 buy was Verve Therapeutics: 635,792 shares worth $21.8M.
  • MPM BioImpact added most to Iovance Biotherapeutics in Q3 2022, an estimated $5.77M increase.
  • MPM BioImpact's biggest Q3 2022 reduction was Mirum Pharmaceuticals, cutting an estimated $4.6M.
  • MPM BioImpact fully exited Epizyme, Inc in Q3 2022, selling an estimated $5.04M.
  • MPM BioImpact's ten largest holdings make up 69% of its $422M portfolio in Q3 2022.
  • MPM BioImpact opened 4 new positions and closed 3 in Q3 2022.
  • MPM BioImpact's portfolio value rose 17% quarter-over-quarter to $422M.

Based on MPM BioImpact's 13F filing for Q3 2022, filed 14 Nov 2022.